Product Pipeline
Women's Health
Product
Target/Type
Region
Pre-Clinical
IND Enabling
Phase I
Phase II
Pivotal/Phase III
NDA
APL-1702
Photodynamic drug-device combination product
Global
Europe,China
Cervical high grade squamous intraepithelial lesions (HSIL) Partner: 
USA
Intend to submit a phase III trial application to FDA
HPV clearance
Urological Diseases
Product
Target/Type
Region
Pre-Clinical
IND Enabling
Phase I
Phase II
Pivotal/Phase III
NDA
APL-1706
Photosensitizer
China
NMIBC diagnosis and operation.
Partner:
APL-1202
MetAP2
Global
China
NMIBC (Second-line treatment in combination with chemotherapy)
China
NMIBC (First-line monotherapy)
USA, China
Neoadjuvant therapy for MIBC (In combination with tislelizumab). Partner: 
China
Last Stage bladder Cancer
Intend to submit a clinical trial application to NMPA
Intend to submit a clinical trial application to NMPA
APL-1501
(Second-generation compound of APL-1202)
MetAP
Global
Australia
Urological tumors/Resistant urological tract infections
APL-2401
FGFR2/3
Global
Urological tumors
APLD -2304
Second generation blue light cystoscope
Global
NMIBC diagnosis and operation.
AT-014
Undisclosed
Global
Urological Tumors
AT-020
Undisclosed
Global
Multiple Solid Tumors
Breast Cancer and Gynecological Tumors
Product
Target/Type
Region
Pre-Clinical
IND Enabling
Phase I
Phase II
Pivotal/Phase III
NDA
APL-2302
USP1
Global
Ovarian cancer, breast cancer, etc
APL-2501
CLDN6/9(ADC)
Global
Ovarian Cancer, etc
AT-018
Undisclosed
Global
Ovarian cancer, breast cancer, etc
AT-021
Undisclosed
Global
Breast cancer and other solid tumors
Other Diseases
Product
Target/Type
Region
Pre-Clinical
IND Enabling
Phase I
Phase II
Pivotal/Phase III
NDA
APL-1202
MetAP2
Global
China
Free-living Amoebae Infections
APL-1401
DBH
Global
USA, China
Moderately to severely active ulcerative colitis (UC).
APL-2301
Antibiotic
Global
Australia
Acinetobacter baumannii infection
1 First-In-Class (Global Pioneer)
